Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.45 |
| ▸ | SGPL1 | O95470 | 7/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18507218 | 1.00 | S1PR1 (0.45) | S1PR1SGPL1S1PR4S1PR5CYP3A4 | |
| SCHEMBL18507191 | 1.00 | S1PR1 (0.45) | S1PR1SGPL1S1PR4S1PR5CYP3A4 | |
| SCHEMBL25862337 | 0.99 | S1PR1 (0.45) | S1PR1SGPL1S1PR4S1PR5CYP3A4 | |
| SCHEMBL22404264 | 0.97 | S1PR1 (0.46) | S1PR1SGPL1S1PR4S1PR5CYP3A4 | |
| SCHEMBL22404195 | 0.96 | SGPL1 (0.47) | S1PR1SGPL1S1PR4S1PR5CYP3A4 | |
| SCHEMBL22404140 | 0.93 | S1PR1 (0.42) | S1PR1SGPL1S1PR4S1PR5CYP3A4 | |
| SCHEMBL23369054 | 0.89 | S1PR1 (0.45) | S1PR1SGPL1S1PR4S1PR5CYP3A4 | |
| SCHEMBL23368712 | 0.89 | S1PR1 (0.45) | S1PR1SGPL1S1PR4S1PR5CYP3A4 | |
| SCHEMBL22404170 | 0.88 | S1PR1 (0.45) | S1PR1SGPL1 | |
| SCHEMBL23368732 | 0.88 | S1PR1 (0.44) | S1PR1SGPL1S1PR4S1PR5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701373-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-18 | — | — | US | disclosed |
| US-11058696-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200281952-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281952-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885SGPL1 75/4885S1PR4 4/4885 |
| US-11701373-B2 | Substituted bicyclic compounds | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885SGPL1 75/4885S1PR4 4/4885 |
| US-11058696-B2 | Substituted bicyclic compounds | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885SGPL1 75/4885S1PR4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.